{
    "ticker": "APLS",
    "name": "Apellis Pharmaceuticals, Inc.",
    "description": "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat autoimmune and rare diseases. Founded in 2009, Apellis is committed to advancing the science of complement inhibition, which plays a critical role in the immune response and is implicated in various diseases. The company's lead product candidate, pegcetacoplan, is designed to target the complement system and is being evaluated for the treatment of geographic atrophy, a severe form of age-related macular degeneration (AMD). Apellis is also exploring its complement-targeting therapies for other indications, including hematologic diseases and immune-mediated disorders. With a strong pipeline and a focus on unmet medical needs, Apellis aims to improve the lives of patients through innovative approaches. The company is headquartered in Waltham, Massachusetts, and has established a robust research and development platform to drive the discovery and development of new therapies. Apellis is dedicated to scientific excellence and collaboration, partnering with healthcare professionals and patient communities to enhance understanding and treatment of complex diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Waltham, Massachusetts, USA",
    "founded": "2009",
    "website": "https://www.apellis.com",
    "ceo": "Cedric Francois, M.D.",
    "social_media": {
        "twitter": "https://twitter.com/ApellisPharma",
        "linkedin": "https://www.linkedin.com/company/apellis-pharmaceuticals/"
    },
    "investor_relations": "https://investors.apellis.com",
    "key_executives": [
        {
            "name": "Cedric Francois, M.D.",
            "position": "CEO"
        },
        {
            "name": "Lindsay A. Rosenwald, M.D.",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Pegcetacoplan"
            ]
        }
    ],
    "seo": {
        "meta_title": "Apellis Pharmaceuticals, Inc. | Innovative Therapies for Autoimmune Diseases",
        "meta_description": "Explore Apellis Pharmaceuticals, Inc., a leader in developing complement-targeted therapies for autoimmune and rare diseases. Learn about our innovative pipeline and commitment to patients.",
        "keywords": [
            "Apellis Pharmaceuticals",
            "Pegcetacoplan",
            "Biotechnology",
            "Autoimmune Diseases",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Apellis Pharmaceuticals known for?",
            "answer": "Apellis Pharmaceuticals is known for developing innovative therapies that target the complement system for treating autoimmune and rare diseases."
        },
        {
            "question": "Who is the CEO of Apellis Pharmaceuticals?",
            "answer": "Cedric Francois, M.D. is the CEO of Apellis Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Apellis headquartered?",
            "answer": "Apellis is headquartered in Waltham, Massachusetts, USA."
        },
        {
            "question": "What is the main product of Apellis Pharmaceuticals?",
            "answer": "The main product of Apellis Pharmaceuticals is pegcetacoplan, which is being developed for geographic atrophy."
        },
        {
            "question": "When was Apellis Pharmaceuticals founded?",
            "answer": "Apellis Pharmaceuticals was founded in 2009."
        }
    ],
    "competitors": [
        "REGN",
        "VRTX",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ABBV",
        "MRNA"
    ]
}